116 lines
No EOL
25 KiB
XML
116 lines
No EOL
25 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547966" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547966/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Buspirone - LiverTox - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Buspirone" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/09/11" /><meta name="citation_pmid" content="31643299" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547966/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Buspirone" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/09/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547966/" /><meta name="description" content="Buspirone is a psychoactive drug used for management of general anxiety disorders and alleviation of the symptoms of anxiety. Despite wide scale use, it is an infrequent cause of serum enzyme elevations and has not been linked to instances of clinically apparent liver injury with jaundice." /><meta name="og:title" content="Buspirone" /><meta name="og:type" content="book" /><meta name="og:description" content="Buspirone is a psychoactive drug used for management of general anxiety disorders and alleviation of the symptoms of anxiety. Despite wide scale use, it is an infrequent cause of serum enzyme elevations and has not been linked to instances of clinically apparent liver injury with jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547966/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Buspirone/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547966/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8E4B357D7B9B9100000000012000F9.m_5" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid no_max_width">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
|
|
<div class="header">
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<div class="container content">
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547966_"><span class="title" itemprop="name">Buspirone</span></h1><p class="small">Last Update: <span itemprop="dateModified">September 11, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Buspirone.OVERVIEW"><h2 id="_Buspirone_OVERVIEW_">OVERVIEW</h2><div id="Buspirone.Introduction"><h3>Introduction</h3><p>Buspirone is a psychoactive drug used for management of general anxiety disorders and alleviation of the symptoms of anxiety. Despite wide scale use, it is an infrequent cause of serum enzyme elevations and has not been linked to instances of clinically apparent liver injury with jaundice.</p></div><div id="Buspirone.Background"><h3>Background</h3><p>Buspirone (bue spye' rone) is an azapirone antianxiety medication that has little or no similarity to the benzodiazepines or barbiturates in its structure or mechanism of action. Buspirone appears to interact with dopamine and serotonin receptors, but its precise mechanism of action in alleviating anxiety is not known. Buspirone was approved for use in the United States in 1986. Current indications are for the treatment of generalized anxiety disorder and amelioration of the symptoms of anxiety. It has been used off label for depression (often in combination with other agents) and as treatment for substance abuse, posttraumatic stress syndrome, bruxism, tardive dyskinesia and other psychiatric and neurological conditions, but its efficacy in these situations has not been proven. Buspirone is available in tablets of 5, 10, 15 and 30 mg in several generic forms and under the brand name Buspar. Typical doses are 15 to 30 mg daily in divided doses. Side effects may include drowsiness, headache, nausea, abdominal discomfort and rash.</p></div><div id="Buspirone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Buspirone has been associated with infrequent serum aminotransferase elevations, but has not been linked to instances of clinically apparent liver injury in the published literature. Indeed, buspirone is often used as a control, noncytotoxic agent in assessment of other psychotropic drugs in vitro and in vivo. Buspirone is, nevertheless, metabolized in the liver by the P450 system (CYP 3A4) and has the potential of causing drug-drug interactions.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p><p>Drug Class: <a href="/books/n/livertox/Sedatives_Hypnotics/">Sedatives and Hypnotics</a>, Miscellaneous</p></div></div><div id="Buspirone.PRODUCT_INFORMATION"><h2 id="_Buspirone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Buspirone.BPI" class="box"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Buspirone – Generic, Buspar®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Sedatives and Hypnotics</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Buspirone" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Buspirone.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Buspirone_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Buspirone.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547966/table/Buspirone.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Buspirone.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Buspirone.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Buspirone.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Buspirone.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Buspirone.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Buspirone.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Buspirone</td><td headers="hd_h_Buspirone.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">36505-84-7</td><td headers="hd_h_Buspirone.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C21-H31-N5-O2</td><td headers="hd_h_Buspirone.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547966/bin/Buspirone_Structure.jpg" alt="Buspirone Chemical Structure" /></div>
|
|
</td></tr></tbody></table></div></div></div><div id="Buspirone.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Buspirone_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 11 September 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Buspirone.R1">Zimmerman HJ. Unconventional drugs. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 731-4.<div><i>(Expert review of hepatotoxicity published in 1999; buspirone is not discussed).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R2">Larrey D, Ripault M-P. Anxiolytic agents. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 455-6.<div><i>(Review of hepatotoxicity of hypnotics and sedatives discusses benzodiazepines, buspirone and valerian all of which have been linked to rare cases of liver injury).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R3">Mihic SJ, Harris RA. Hypnotics and sedatives. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 457-80.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R4">Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290-6. [<a href="https://pubmed.ncbi.nlm.nih.gov/2866493" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2866493</span></a>]<div><i>(Controlled trial of buspirone vs diazepam in 66 patients with anxiety disorders found similar efficacy and fewer side effects with buspirone and "no significant differences in either groups in final laboratory assessments").</i></div></div></li><li><div class="bk_ref" id="Buspirone.R5">Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med 1986; 80 (3B): 17-21. [<a href="https://pubmed.ncbi.nlm.nih.gov/2870641" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2870641</span></a>]<div><i>(Analysis of side effects among 984 patients with general anxiety disorders treated with buspirone in controlled trials; side effects occurring more often with buspirone than placebo included dizziness [9% vs 2%], headache [7% vs 2%], nervousness, diarrhea, paresthesias, excitation and sweating; laboratory test results were not discussed).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R6">Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther 1988; 10: 740-6. [<a href="https://pubmed.ncbi.nlm.nih.gov/3219687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3219687</span></a>]<div><i>(Open label postmarketing study of buspirone in 6000 patients; side effects were reported in 6-7% of patients, but no laboratory results were reported).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R7">Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology1989; 21 (3): 124-30. [<a href="https://pubmed.ncbi.nlm.nih.gov/2615929" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2615929</span></a>]<div><i>(Pooled data on 427 patients with anxiety disorders treated with buspirone [10 to 60 mg daily] for 4 weeks; "the beneficial effects of buspirone were not compromised by any significant side effects").</i></div></div></li><li><div class="bk_ref" id="Buspirone.R8">Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990; 83: 194-8. [<a href="https://pubmed.ncbi.nlm.nih.gov/2406933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2406933</span></a>]<div><i>(Among 424 patients with chronic anxiety treated with buspirone for at least 6 months, side effects were mild to moderate in severity and "clinical laboratory tests, including hematologic and hepatic indices, revealed no clinically significant changes attributable to buspirone").</i></div></div></li><li><div class="bk_ref" id="Buspirone.R9">Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1-11. [<a href="https://pubmed.ncbi.nlm.nih.gov/8372689" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8372689</span></a>]<div><i>(Controlled trial of buspirone vs alprazolam vs placebo in 92 patients with panic disorders identified no changes in laboratory test results in buspirone treated subjects).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R10">Sramek JJ, Frackiewicz EJ, Cutler NR. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clin Ther 1997; 19: 498-506. [<a href="https://pubmed.ncbi.nlm.nih.gov/9220214" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9220214</span></a>]<div><i>(Controlled trial of 2 doses of buspirone in 137 patients with anxiety disorders; common side effects were dizziness, headache, nausea, diarrhea and somnolence; there were no differences in laboratory test results in the treated patients).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R11">Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety 1999; 9: 131-4. [<a href="https://pubmed.ncbi.nlm.nih.gov/10356651" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10356651</span></a>]<div><i>(Pooled analysis of safety in studies of two doses of buspirone found no differences in laboratory tests and no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R12">McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009; 105: 132-8. [<a href="/pmc/articles/PMC2789590/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2789590</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19699593" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19699593</span></a>]<div><i>(Controlled trial of 12 weeks of buspirone vs placebo in 50 patients with marijuana dependence found no serious adverse events, but no laboratory test results reported).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R13">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. <em> (Among 300</em>. [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>cases of drug induced liver disease in the US collected from 2004 to 2008, 14 were attributed to antidepressants, including 6 to duloxetine, 3 atomoxetine, 2 fluoxetine, 2 bupropion, and 1 sertraline, but none to buspirone).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R14">Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71: 839-54. [<a href="https://pubmed.ncbi.nlm.nih.gov/20667290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20667290</span></a>]<div><i>(Review of the use of medications for anxiety disorders including tricyclic antidepressants, MAO inhibitors, SSRIs, benzodiazepines and buspirone states that buspirone has good tolerability and low potential for dependence but is of limited efficacy).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R15">Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011; 12: 2457-67. [<a href="https://pubmed.ncbi.nlm.nih.gov/21950420" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21950420</span></a>]<div><i>(Review of pharmacological therapy of anxiety disorders, the first line agents being the SSRIs and SNRIs; buspirone has comparable but slightly weaker efficacy compared to benzodiazepines; no mention of adverse events).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R16">Loane C, Politis M. Buspirone: what is it all about? Brain Res 2012; 1461: 111-8. [<a href="https://pubmed.ncbi.nlm.nih.gov/22608068" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22608068</span></a>]<div><i>(Review of efficacy and safety of buspirone and its use in other conditions such as depression, ataxia, dyskinesia and obsessive compulsive disorder; no discussion of adverse events).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R17">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9. [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to buspirone).</i></div></div></li><li><div class="bk_ref" id="Buspirone.R18">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to buspirone or other sedative or antianxiety medications).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547966</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643299" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643299</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Burosumab/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Busulfan/" title="Next page in this title">Next ></a></div></div></div></div>
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK547966&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK547966/?report=printable&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |